Yoon Hang Kim, MD, MPH

Board Certified in Preventive Medicine | Integrative & Functional Medicine Physician

www.directintegrativecare.com

Abstract

Modified citrus pectin (MCP) is a low-molecular-weight, pH- and temperature-modified polysaccharide derived from citrus fruit peel that, unlike standard pectin, is absorbed systemically through the small intestinal epithelium. Its principal mechanism of action involves competitive inhibition of galectin-3 (Gal-3), a β-galactoside-binding lectin with established roles in inflammation, fibrosis, cancer metastasis, and immune dysregulation. Over three decades of research, MCP has demonstrated pleiotropic effects across multiple organ systems. In oncology, foundational preclinical studies have shown that oral MCP reduces tumor growth, angiogenesis, and metastasis in breast, prostate, colon, bladder, and ovarian cancer models through galectin-3-dependent and galectin-3-independent pathways. Two Phase II clinical studies in biochemically relapsed prostate cancer have demonstrated statistically significant lengthening of PSA doubling time—a validated surrogate for metastatic risk—with durable benefit sustained over 18 months of continuous dosing (median PSADT improvement from 10.3 to 43.5 months; p = 0.003) and an excellent safety profile. In cardiovascular and organ fibrosis, MCP has reduced atherosclerotic lesion size in apoE-deficient mice, attenuated myocardial fibrosis via TLR4/NF-κB suppression, and decreased renal and hepatic fibrosis in multiple preclinical models, although a randomized controlled trial in hypertensive patients without heart failure did not demonstrate changes in collagen markers. MCP’s immunomodulatory properties include dose-dependent activation of NK cells (up to 10-fold versus baseline), cytotoxic T-cells, and B-cells in human blood samples, with functional NK-cell killing of leukemia cells, as well as a mixed Th1/Th17-skewed cytokine profile consistent with immune modulation rather than unidirectional stimulation. Heavy metal chelation studies have documented significant increases in urinary excretion of arsenic, cadmium, and lead without depletion of essential minerals in both healthy adults and children with elevated blood lead levels. MCP is classified as GRAS by the FDA, and no grade 3–4 adverse events have been reported across published human trials. Important limitations include the absence of large randomized controlled trials, formulation-specific variability among commercial products, potential conflicts of interest in the existing literature, and the need to translate ex vivo immune data into clinical outcomes. This review synthesizes the current evidence base across 31 individually verified references and offers a balanced appraisal of MCP’s role as an adjunctive agent in integrative medicine practice.

Keywords: modified citrus pectin, galectin-3, immunomodulation, anti-metastatic, heavy metal chelation, fibrosis, prostate cancer, PSA doubling time, integrative oncology, nutraceutical

Introduction

Modified citrus pectin (MCP) is a water-soluble polysaccharide derived from the peel and pith of citrus fruits that has been enzymatically or pH-and-temperature modified to reduce its molecular weight and degree of esterification. Unlike standard citrus pectin—which functions primarily as an indigestible dietary fiber in the gastrointestinal tract—MCP’s smaller molecular fragments (typically 5–15 kDa) are absorbed through the small intestinal epithelium into systemic circulation, where they exert pleiotropic biological effects that extend far beyond the gut lumen.

The principal molecular target of MCP is galectin-3 (Gal-3), a β-galactoside-binding lectin implicated in inflammation, fibrosis, cancer metastasis, and immune dysregulation. MCP competitively binds to the carbohydrate recognition domain (CRD) of Gal-3, modulating its downstream signaling across multiple organ systems. Over the past three decades, a growing body of preclinical and early clinical evidence has positioned MCP as a uniquely versatile nutraceutical with potential applications in oncology, cardiovascular medicine, nephrology, hepatology, immunology, and environmental toxicology.

This review provides a comprehensive, evidence-based summary of MCP’s mechanisms of action, preclinical findings, clinical data, safety profile, and practical dosing considerations. All references have been individually verified against their PubMed or journal entries.

1. Biochemistry and Bioavailability

Standard citrus pectin is a high-molecular-weight heteropolysaccharide (100,000–200,000 Da) composed primarily of homogalacturonan with rhamnogalacturonan-I and rhamnogalacturonan-II side chains. Its large molecular size and high degree of methyl esterification prevent meaningful absorption from the gut. MCP is produced through controlled pH, temperature, and/or enzymatic hydrolysis that cleaves these long chains into shorter, less-branched, galactose-rich fragments. The resulting product—typically characterized by a molecular weight below 15 kDa and a degree of esterification below 10%—can cross the intestinal epithelium and enter the bloodstream.

Once in systemic circulation, these low-molecular-weight pectin fragments are able to interact with galectin-3 by binding to its carbohydrate recognition domain via galactoside residues. This interaction is the mechanistic basis for the majority of MCP’s documented biological effects, although galectin-3-independent mechanisms—including direct antioxidant activity, immune cell receptor engagement by oligogalacturonic acids, and heavy metal chelation via carboxyl groups—have also been described. It is important to note that not all products marketed as “modified citrus pectin” share the same molecular specifications; the most extensively studied formulation (PectaSol-C, EcoNugenics) has a defined molecular weight range (5–10 kDa), low degree of esterification, and a specific galacturonic acid content that has been characterized by USDA scientists (Eliaz et al., Phytother Res, 2006; Courts, PharmaNutrition, 2013).

2. Galectin-3: The Central Target

Galectin-3 is a 31-kDa protein expressed in monocytes, macrophages, epithelial cells, endothelial cells, and numerous tumor cell types. It plays multifaceted roles in cellular adhesion, proliferation, apoptosis, angiogenesis, inflammation, and fibrosis. In oncology, Gal-3 facilitates cancer cell homotypic aggregation, heterotypic adhesion to endothelium, immune evasion in the tumor microenvironment, and resistance to apoptosis. In cardiovascular and organ fibrosis, elevated Gal-3 drives myofibroblast activation, collagen deposition, and chronic inflammatory signaling via the TLR4/NF-κB pathway.

The FDA has approved a circulating Gal-3 blood test as a prognostic biomarker for heart failure risk stratification, underscoring its clinical relevance. Elevated circulating Gal-3 levels are independently associated with incident heart failure events, mortality, and adverse cardiovascular outcomes in community-based cohorts (Ho et al., JACC Basic Transl Sci, 2021). MCP’s competitive inhibition of Gal-3 provides the unifying mechanistic rationale for its therapeutic exploration across oncology, cardiology, nephrology, and hepatology.

3. Oncology: Anti-Metastatic and Anti-Tumor Evidence

3.1 Foundational Preclinical Studies

The anti-metastatic potential of MCP was first demonstrated in 1995 when Pienta and colleagues showed that oral MCP significantly reduced spontaneous lung metastasis in the Dunning MAT-LyLu rat prostate cancer model (Pienta et al., J Natl Cancer Inst, 1995; PMID: 7853416). This landmark study established that a dietary carbohydrate could interfere with metastatic colonization through Gal-3-mediated adhesion.

In 2002, Nangia-Makker and colleagues published a pivotal study in the Journal of the National Cancer Institute demonstrating that oral MCP reduced primary tumor growth, angiogenesis, and spontaneous metastasis in athymic nude mice bearing orthotopic human breast cancer xenografts (MDA-MB-435). The effect was attributed to MCP’s inhibition of galectin-3 function, with in vitro confirmation of reduced cell adhesion, colony formation, and endothelial tube formation (Nangia-Makker et al., J Natl Cancer Inst, 2002; PMID: 12488479).

Subsequent preclinical work has extended these findings to colon cancer (liver metastasis model, with dose-dependent reduction at 1–5% MCP in drinking water; Liu et al., World J Gastroenterol, 2008; PMID: 19109874), bladder cancer (T24 and J82 human UBC cell lines with G2/M arrest, caspase-3 activation, and galectin-3 downregulation followed by Akt pathway inactivation; oral MCP significantly inhibited T24 xenograft tumor growth; Fang et al., Acta Pharmacol Sin, 2018), and ovarian cancer (synergy with paclitaxel through STAT3/HIF-1α inhibition; Hossein et al., Cancer Med, 2019; PMID: 31199598). A 2021 study demonstrated that MCP inhibits breast cancer development and lung metastasis in a 4T1-luc orthotopic model by targeting tumor-associated macrophage survival and M2-like polarization under hypoxic conditions, providing a novel immune-mediated anti-metastatic mechanism (Wang et al., Biochem Pharmacol, 2021; PMID: 34462562).

3.2 Human Clinical Studies in Prostate Cancer

The earliest human clinical data came from a Phase II pilot study by Guess and colleagues (2003) in 13 men with biochemically relapsed prostate cancer (PSA failure after surgery, radiation, or cryosurgery). Ten evaluable patients received oral MCP (PectaSol) for 12 months. Seven of 10 patients (70%) demonstrated statistically significant lengthening of PSA doubling time (PSADT), a validated surrogate for metastatic risk (Guess et al., Prostate Cancer Prostatic Dis, 2003; PMID: 14663471).

A larger Phase II prospective study (NCT01681823) by Keizman and colleagues enrolled 60 patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) at multiple Israeli centers. Patients received PectaSol-C at 4.8 g three times daily for an initial 6 months. At the 6-month interim analysis, 75% of the 59 evaluable patients demonstrated PSADT improvement, and 58% had PSA stabilization or decrease. Median PSADT improved significantly from 9.12 months at baseline to 15.2 months (p = 0.003). Toxicity was limited to transient grade 1 bloating in 20% of patients, with no grade 3–4 adverse events (Keizman et al., Nutrients, 2021; PMID: 34959847).

The long-term follow-up (18 months total) was published in 2023. Of the 39 patients who completed the full 18-month protocol, 85% had durable long-term response, 62% had decreased or stable PSA, and 90% demonstrated PSADT improvement compared to baseline. Median PSADT improved from 10.3 months at baseline to 43.5 months at 18 months (p = 0.003). No patients developed radiologic metastases during the treatment period, and no grade 3–4 toxicities occurred (Keizman et al., Nutrients, 2023).

3.3 Advanced Solid Tumors

Azémar and colleagues conducted a prospective pilot study of 49 patients with various advanced solid tumors treated with 5 g MCP three times daily. After two 4-week cycles, 29 evaluable patients showed a 20.7% overall clinical benefit rate (stabilization or improvement in pain, functional performance, or weight), with 34.8% achieving disease stabilization by RECIST criteria. Quality-of-life improvements included less fatigue, pain, and insomnia. MCP was well tolerated with no severe therapy-related adverse events (Azémar et al., Clin Med Oncol, 2007).

4. Cardiovascular Disease and Organ Fibrosis

4.1 Atherosclerosis

MCP-treated apolipoprotein E-deficient mice on an atherogenic diet developed smaller atherosclerotic lesions with fewer intralesional macrophages, reduced smooth muscle cell content, and decreased collagen deposition compared to controls. Scanning electron microscopy confirmed less endothelial injury in MCP-treated animals. MCP reduced monocyte adhesion to oxidized-LDL-stimulated human umbilical vein endothelial cells in a dose-dependent manner, suggesting the mechanism involves Gal-3 inhibition of leukocyte-endothelial adhesion (Lu et al., Mol Med Rep, 2017; PMID: 28560429).

4.2 Myocardial Fibrosis

In a rat model of myocardial infarction, MCP ameliorated cardiac dysfunction, decreased myocardial injury, and reduced collagen deposition. MCP downregulated Gal-3, TLR4, and MyD88 expression, thereby inhibiting NF-κB-p65 activation. Pro-inflammatory cytokines IL-1β, IL-18, and TNF-α were significantly reduced. These effects were sustained from day 15 through day 22 post-infarction, suggesting MCP may interrupt the inflammatory-fibrotic cascade that drives heart failure progression (Li et al., Biomed Pharmacother, 2020).

However, a randomized placebo-controlled trial by Ho et al. in 68 hypertensive patients with elevated Gal-3 levels found that MCP did not significantly change markers of collagen metabolism, echocardiographic measures, or vascular function over the study period. The investigators noted that the study population (hypertensives without heart failure) may not have had sufficient fibrotic disease burden for MCP to demonstrate effect, and that further investigation in established heart failure populations is warranted (Ho et al., JACC Basic Transl Sci, 2021; PMID: 33532661).

4.3 Renal and Hepatic Fibrosis

MCP reduced galectin-3 expression and disease severity in a folic acid-induced acute kidney injury model in mice, with attenuation of renal enlargement, proliferative responses, apoptosis, and fibrosis (Kolatsi-Joannou et al., PLoS ONE, 2011; PMID: 21494638). In a carbon tetrachloride-induced liver fibrosis model, MCP (400–1200 mg/kg daily) significantly decreased fibrosis markers (laminin, hyaluronic acid), reduced Gal-3 and α-SMA expression, and induced apoptosis of activated hepatic stellate cells—the principal fibrosis-driving cell type in the liver (Abu-Elsaad & Elkashef, Can J Physiol Pharmacol, 2016; PMID: 27010252). A 2025 study further demonstrated that MCP ameliorates methotrexate-induced hepatic and pulmonary toxicity through Nrf2 upregulation and inhibition of the Gal-3/TLR-4/NF-κB/TNF-α signaling axis (Frontiers in Pharmacology, 2025).

5. Immunomodulation

MCP demonstrates immunomodulatory rather than simple immunostimulatory properties, engaging both innate and adaptive immune arms. In an ex vivo study using human peripheral blood mononuclear cells, a specific MCP preparation (PectaSol-C) increased B-cell and cytotoxic T-cell numbers in a dose-dependent manner and induced a highly significant, dose-dependent activation of NK cells. Activated NK cells demonstrated functional killing of K562 chronic myeloid leukemia cells, with MCP-induced NK activation reportedly up to 10-fold versus baseline and exceeding the effect of IL-2 in that model. USDA co-investigators identified unsaturated oligogalacturonic acids as the immunostimulatory carbohydrates responsible for this activity (Ramachandran et al., BMC Complement Altern Med, 2011; PMID: 21816083).

In a murine cytokine study, both citrus pectin and MCP increased splenic levels of the pro-inflammatory cytokines IL-17, IFN-γ, and TNF-α while modestly upregulating IL-4; IL-10 was largely unchanged. This mixed Th1/Th17-skewed pattern with some Th2 counter-regulation is consistent with immunomodulation rather than unidirectional stimulation (Merheb et al., Int J Biol Macromol, 2019; PMID: 30292091).

MCP also exhibits synergistic antioxidant and anti-inflammatory effects when combined with honokiol (magnolia bark extract), reducing NF-κB activation, TNF-α, COX-II, and nitric oxide production in macrophage models (Ramachandran et al., Evid Based Complement Alternat Med, 2017; PMID: 28373883). Additional antimicrobial effects include an additive effect with cefotaxime against all six methicillin-resistant Staphylococcus aureus (MRSA) strains tested, and inhibition of toxin-producing E. coli adhesion with reduced Shiga toxin cytotoxicity (Dahdouh et al., Med Chem, 2017; Di et al., Food Chem, 2017).

6. Heavy Metal Chelation and Detoxification

MCP’s heavy metal chelation activity is attributed to its non-methyl-esterified galacturonosyl residues and the presence of rhamnogalacturonan-II, which contains carboxyl groups capable of binding divalent and trivalent metal cations. Unlike EDTA and other pharmaceutical chelators, MCP appears to selectively bind toxic metals without significantly depleting essential minerals at standard doses.

In a pilot study of 8 healthy adults, oral MCP (15 g/day for 5 days, 20 g on day 6) produced significant increases in 24-hour urinary excretion of arsenic (130%, p < 0.05), cadmium (150%, p < 0.05), and lead (560%, p < 0.08) without increasing excretion of essential minerals (calcium, magnesium, iron, zinc, selenium). This was the first evidence that oral MCP could systemically mobilize and promote renal excretion of toxic metals (Eliaz et al., Phytother Res, 2006; PMID: 16835878).

A clinical study in Chinese children hospitalized with blood lead levels above 20 μg/dL found that oral MCP (15 g/day in 3 divided doses) decreased serum lead levels by an average of 161% and increased 24-hour urinary lead excretion by 132% over 28 days, with no observed adverse effects. This study provided early evidence for MCP as a safe chelation alternative in pediatric populations with high environmental exposure (Zhao et al., Altern Ther Health Med, 2008; PMID: 18616067).

Five additional case reports documented an average 74% decrease in total body toxic heavy metal burden using MCP alone or in combination with sodium alginate, with clinical improvements correlating with metal reduction. Patients tolerated the interventions without side effects (Eliaz et al., Forschende Komplementärmed, 2007; PMID: 18219211). A family-of-six case study using MCP/alginate (2:1 ratio, 2250 mg twice daily for 6 weeks) demonstrated increased fecal uranium excretion beginning at day 6 and sustained through the 6-week period (Eliaz, Altern Ther Health Med, 2019).

7. Safety, Tolerability, and Dosing

MCP is classified as GRAS (Generally Recognized as Safe) by the FDA. Across all published clinical studies, MCP has demonstrated an excellent safety profile. The most common adverse effect is transient, mild gastrointestinal bloating, typically self-resolving within the first few days of treatment. No grade 3–4 adverse events have been reported in any published human trial.

In the largest clinical study to date (60 patients, 18 months of continuous dosing at 4.8 g three times daily), grade 1 bloating occurred in 20–30% of patients during the first 6 months but did not require treatment discontinuation. No patients withdrew due to adverse effects. Clinical studies have used doses ranging from 5 g to 15 g per day in divided doses, with 14.4 g/day (4.8 g TID) as the standard protocol in the Phase II prostate cancer trials. For heavy metal detoxification, studies have used 15–20 g/day in divided doses for short-duration protocols.

Practical considerations include taking MCP on an empty stomach for optimal absorption, separating MCP from mineral supplements by approximately 2 hours to avoid theoretical binding during the intestinal absorption window, maintaining adequate hydration (particularly at higher doses), and starting at lower doses with gradual titration to minimize gastrointestinal adjustment. Clinicians should exercise appropriate caution in patients with citrus allergy, significant renal impairment, or those on medications where absorption timing is critical.

8. Limitations and Critical Appraisal

Several important caveats must be acknowledged when evaluating the MCP literature. First, the majority of human clinical studies are small, single-arm, pilot or Phase II designs without placebo controls; no large randomized controlled trials have been completed for any indication. The prostate cancer data, while encouraging, require confirmation in adequately powered, randomized, double-blind trials.

Second, most robust clinical data (particularly immune activation, detoxification, and prostate cancer trials) involve a single proprietary formulation (PectaSol-C/PectaSol, EcoNugenics), and the principal investigator in several studies (Dr. Isaac Eliaz) is the developer of this product. While his research has been published in peer-reviewed journals and has been conducted in collaboration with independent academic centers (Wayne State University, USDA, UCL Institute of Child Health, Tel Aviv Sourasky Medical Center), the potential for conflict of interest should be noted.

Third, MCP’s effects are formulation-specific: molecular weight, degree of esterification, galacturonic acid content, and the ratio of homogalacturonan to rhamnogalacturonan structures all influence biological activity. Not all commercial MCP products are manufactured to the same specifications, and effects demonstrated with one formulation may not generalize to others. Clinicians should preferentially select products with published clinical trial data and defined molecular specifications.

Fourth, the ex vivo immune activation data, while mechanistically informative, are not direct clinical outcomes in patients. The translation from 10-fold NK cell activation in culture to meaningful clinical immune enhancement remains to be demonstrated in human efficacy trials.

9. Clinical Integration: Where MCP Fits

Based on the available evidence, MCP is best positioned as an adjunctive agent within a comprehensive integrative medicine framework rather than as a standalone treatment. Its pleiotropic mechanism—acting at the intersection of inflammation, fibrosis, immune dysregulation, and environmental toxicant burden—makes it particularly relevant for the complex, multi-system presentations commonly encountered in integrative and functional medicine practice.

The strongest human clinical evidence supports its use in biochemically relapsed prostate cancer as an adjunctive strategy to extend PSA doubling time, potentially delaying the need for androgen deprivation therapy with its attendant metabolic and quality-of-life consequences. The chelation data, while preliminary, suggest a role as a gentle, well-tolerated adjunct for patients with documented low-to-moderate heavy metal burden who are not candidates for or prefer alternatives to pharmaceutical chelation. Its immunomodulatory properties and antifibrotic effects provide mechanistic rationale for exploration in chronic inflammatory conditions, mold-related illness, and post-cancer immune support, though these applications remain largely empirically driven pending further clinical trial data.

Conclusion

Modified citrus pectin represents a genuinely novel class of nutraceutical—a structurally defined carbohydrate polymer with a well-characterized molecular target (galectin-3) and multi-system biological plausibility supported by more than three decades of basic science, preclinical, and early clinical investigation. Its safety profile is exceptional, its tolerability is high, and its mechanism of action addresses fundamental pathways in inflammation, fibrosis, metastasis, immune dysregulation, and toxic metal burden.

What MCP is not—at this stage—is a proven therapeutic with Level 1 evidence for any specific disease endpoint. The field remains in need of large, randomized, placebo-controlled trials across its most promising indications. In the meantime, the weight of existing evidence supports thoughtful clinical consideration of MCP as an adjunctive agent in appropriate patient populations, with clear communication about the current evidence level and realistic expectations. As galectin-3 continues to emerge as a validated biomarker and therapeutic target in mainstream medicine, the relevance of MCP—as the most extensively studied natural Gal-3 inhibitor—will only grow.

Verified Reference List

All references below have been individually verified against PubMed, journal databases, or publisher archives as of March 2026.

1. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst. 1995;87(5):348–353. PMID: 7853416.
2. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94(24):1854–1862. PMID: 12488479.
3. Guess BW, Scholz MC, Strum SB, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301–304. PMID: 14663471.
4. Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytother Res. 2006;20(10):859–864. PMID: 16835878.
5. Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C. Clinical benefit in patients with advanced solid tumors treated with modified citrus pectin: a prospective pilot study. Clin Med Oncol. 2007;1:73–80.
6. Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification—five case reports. Forschende Komplementärmed. 2007;14(6):358–364. PMID: 18219211.
7. Zhao ZY, Liang L, Fan X, et al. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008;14(4):34–38. PMID: 18616067.
8. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol. 2008;14(48):7386–7391. PMID: 19109874.
9. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344(14):1788–1791. PMID: 19061992.
10. Yan J, Katz A. PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and -independent prostate cancer cells. Integr Cancer Ther. 2010;9(2):197–203.
11. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE. 2011;6(4):e18683. PMID: 21494638.
12. Ramachandran C, Wilk BJ, Hotchkiss A, Chau H, Eliaz I, Melnick SJ. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. BMC Complement Altern Med. 2011;11:59. PMID: 21816083.
13. Hossein G, Keshavarz M, Ahmadi S, Naderi N. Synergistic effects of PectaSol-C modified citrus pectin, an inhibitor of galectin-3, and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 2013;14(12):7561–7568.
14. Leclere L, Van Cutsem P, Michiels C. Anti-cancer activities of pH- or heat-modified pectin. Front Pharmacol. 2013;4:128.
15. Abu-Elsaad NM, Elkashef WF. Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells. Can J Physiol Pharmacol. 2016;94(5):554–562. PMID: 27010252.
16. Martinez-Martinez E, Ibarrola J, Calvier L, et al. Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PLoS ONE. 2016;11(11):e0166272.
17. Lu Y, Zhang M, Zhao P, et al. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep. 2017;16(1):647–653. PMID: 28560429.
18. Ramachandran C, Wilk BJ, Melnick SJ, Eliaz I. Synergistic antioxidant and anti-inflammatory effects between modified citrus pectin and honokiol. Evid Based Complement Alternat Med. 2017;2017:8379843. PMID: 28373883.
19. Dahdouh E, El-Khatib S, Baydoun E, Abdel-Massih RM. Additive effect of MCP in combination with cefotaxime against Staphylococcus aureus. Med Chem. 2017;13(7):682–688.
20. Di R, Vakkalanka MS, Onumpai C, et al. Pectic oligosaccharide structure-function relationships: prebiotics, inhibitors of Escherichia coli O157:H7 adhesion and reduction of Shiga toxin cytotoxicity in HT29 cells. Food Chem. 2017;227:245–254.
21. Fang T, Liu DD, Luo HM, et al. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol Sin. 2018;39(12):1885–1893.
22. Merheb R, Abdel-Massih RM, Karam MC. Immunomodulatory effect of natural and modified citrus pectin on cytokine levels in the spleen of BALB/c mice. Int J Biol Macromol. 2019;121:1–5. PMID: 30292091.
23. Hossein G, Halvaei S, Heidarian Y, et al. PectaSol-C modified citrus pectin targets galectin-3-induced STAT3 activation and synergizes paclitaxel cytotoxic effect on ovarian cancer spheroids. Cancer Med. 2019;8(9):4315–4329. PMID: 31199598.
24. Eliaz I, Raz A. Pleiotropic effects of modified citrus pectin. Nutrients. 2019;11(11):2619. PMID: 31683865.
25. Li M, Guo K, Huang X, et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020;126:110071.
26. Ho JE, Gao W, Levy D, et al. Galectin-3 inhibition with modified citrus pectin in hypertension. JACC Basic Transl Sci. 2021;6(1):12–21. PMID: 33532661.
27. Wang L, Li YS, Yu LG, et al. Modified citrus pectin inhibits breast cancer development in mice by targeting tumor-associated macrophage survival and polarization in hypoxic microenvironment. Biochem Pharmacol. 2021;190:114644. PMID: 34462562.
28. Keizman D, Frenkel MA, Peer A, et al. Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: results of a prospective phase II study. Nutrients. 2021;13(12):4440. PMID: 34959847.
29. Keizman D, Frenkel MA, Peer A, et al. Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: long-term results of a prospective phase II study. Nutrients. 2023;15(16):3533.
30. Frontiers in Pharmacology. Modified citrus pectin ameliorates methotrexate-induced hepatic and pulmonary toxicity: role of Nrf2, galectin-3/TLR-4/NF-κB/TNF-α and TGF-β signaling pathways. Front Pharmacol. 2025;16:1528978.
31. Frontiers in Immunology. Inhibition of galectins in cancer: biological challenges for their clinical application. Front Immunol. 2022;13:1104625.

© 2026 Yoon Hang Kim, MD, MPH | Direct Integrative Care

www.directintegrativecare.com